Lanreotide in metastatic enteropancreatic neuroendocrine tumors

Guido Rindi, Martyn E. Caplin, Marianne Pavel, Jarosław B. Ćwikła, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Alison Langley, Séverine Martinez, Joëlle Blumberg, Philippe Ruszniewski

Research output: Contribution to journalArticle

513 Citations (Scopus)


Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited.
Original languageEnglish
Pages (from-to)224-233
Number of pages10
JournalNew England Journal of Medicine
Publication statusPublished - 2014


  • Aged
  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Diarrhea
  • Disease-Free Survival
  • Double-Blind Method
  • Female
  • Gastrointestinal Neoplasms
  • Humans
  • Male
  • Middle Aged
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms
  • Peptides, Cyclic
  • Somatostatin


Dive into the research topics of 'Lanreotide in metastatic enteropancreatic neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this